Stockreport

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

AtaiBeckley Inc.  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF BPL-003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned [Read more]